What is Zacks Research’s Estimate for ResMed Q3 Earnings?

ResMed Inc. (NYSE:RMD) – Investment analysts at Zacks Research increased their Q3 2025 earnings estimates for shares of ResMed in a research report issued to clients and investors on Wednesday, February 19th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings of $2.33 per share for the quarter, up from their previous estimate of $2.30. The consensus estimate for ResMed’s current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed’s Q4 2025 earnings at $2.39 EPS, FY2025 earnings at $9.35 EPS, Q1 2026 earnings at $2.28 EPS, Q2 2026 earnings at $2.37 EPS, Q3 2026 earnings at $2.50 EPS, FY2026 earnings at $9.63 EPS, Q1 2027 earnings at $2.49 EPS, Q2 2027 earnings at $2.60 EPS and FY2027 earnings at $10.61 EPS.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%.

A number of other analysts have also issued reports on the stock. Stifel Nicolaus started coverage on shares of ResMed in a research note on Friday, December 13th. They set a “hold” rating and a $250.00 price target on the stock. KeyCorp boosted their price target on shares of ResMed from $266.00 to $280.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. JPMorgan Chase & Co. boosted their price target on shares of ResMed from $270.00 to $286.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. Needham & Company LLC restated a “hold” rating on shares of ResMed in a research note on Friday, January 31st. Finally, The Goldman Sachs Group assumed coverage on shares of ResMed in a research note on Thursday, January 16th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $244.73.

ResMed Trading Down 0.5 %

NYSE RMD opened at $231.61 on Friday. The firm’s 50-day moving average is $237.43 and its two-hundred day moving average is $239.07. ResMed has a 12 month low of $170.56 and a 12 month high of $263.05. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. The stock has a market capitalization of $34.02 billion, a P/E ratio of 27.34, a PEG ratio of 1.53 and a beta of 0.70.

ResMed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Thursday, February 13th. This represents a $2.12 annualized dividend and a dividend yield of 0.92%. ResMed’s payout ratio is currently 25.03%.

Insiders Place Their Bets

In related news, CEO Michael J. Farrell sold 8,009 shares of the business’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $236.77, for a total value of $1,896,290.93. Following the completion of the transaction, the chief executive officer now owns 455,472 shares of the company’s stock, valued at approximately $107,842,105.44. The trade was a 1.73 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $245.65, for a total transaction of $491,300.00. Following the completion of the transaction, the director now directly owns 81,218 shares of the company’s stock, valued at $19,951,201.70. The trade was a 2.40 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,147 shares of company stock worth $2,905,745. Corporate insiders own 0.71% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Peak Financial Advisors LLC purchased a new stake in shares of ResMed during the 4th quarter worth about $2,972,000. Principal Financial Group Inc. increased its position in ResMed by 2.9% in the third quarter. Principal Financial Group Inc. now owns 186,776 shares of the medical equipment provider’s stock worth $45,596,000 after buying an additional 5,284 shares during the period. Spire Wealth Management grew its stake in shares of ResMed by 11.3% in the fourth quarter. Spire Wealth Management now owns 10,800 shares of the medical equipment provider’s stock worth $2,470,000 after purchasing an additional 1,100 shares in the last quarter. Retireful LLC bought a new position in ResMed during the third quarter valued at about $742,000. Finally, Asset Management One Co. Ltd. boosted its stake in ResMed by 2.8% during the fourth quarter. Asset Management One Co. Ltd. now owns 60,489 shares of the medical equipment provider’s stock valued at $14,105,000 after buying an additional 1,629 shares in the last quarter. Institutional investors and hedge funds own 54.98% of the company’s stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.